Antidote
DECEMBER 22, 2022
Antidote’s robust partner network, consisting of over 300 organizations , is made up of patient advocacy groups, point-of-care-companies, health influencers, and more. Though each organization we partner with is unique and multi-faceted, they all share similar goals, one of which is: connecting their communities with resources and research opportunities that can drive medical progress or improve an individual’s quality of life.
Drug Patent Watch
DECEMBER 19, 2022
Annual Drug Patent Expirations for OFORTA Oforta is a drug marketed by Sanofi Aventis Us and is included in one NDA. There is one patent protecting this drug. This drug…. The post New patent expiration for Sanofi Aventis drug OFORTA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
DECEMBER 20, 2022
Whew. It was quite a year—one filled with big deals, big news, and big legislation. Drug Channels also had a big 2022. We now have 35,000 LinkedIn followers , almost 25,000 email subscribers , and nearly 16,000 Twitter followers. Thank you, dear readers, for welcoming me into your inboxes and browsers each week. I’ve had a blast writing Drug Channels and hope that you had fun reading it.
Sygnature Discovery
DECEMBER 22, 2022
Sygnature Discovery joins four of the top ten global pharma companies, Cancer Research Horizons , Manchester Cancer Research Centre (MCRC) and over 20 Contract Research Organisations (CROs) to support innovation in oncology through the second Oncology Development Programme (ODP2). The initiative aims to accelerate development of high impact novel cancer innovations with delivery of the programme overseen by Lean Life Science.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Antidote
DECEMBER 20, 2022
At Antidote, we consider the patient voice in how we think about the entire clinical trial process. From recruitment to randomization, the patient journey is a driving force in all that we do — and we think this strategy is helpful for clinical trial sponsors, as well. Designing treatments, clinical trials, and health solutions around patients practicing patient centricity, and it can have key benefits for everyone involved.
Drug Patent Watch
DECEMBER 22, 2022
This chart shows the drugs with the most patents in Czech Republic. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in Czech Republic? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Sygnature Discovery
DECEMBER 22, 2022
Sygnature Discovery joins four of the top ten global pharma companies, Cancer Research Horizons , Manchester Cancer Research Centre (MCRC) and over 20 Contract Research Organisations (CROs) to support innovation in oncology through the second Oncology Development Programme (ODP2). The initiative aims to accelerate development of high impact novel cancer innovations with delivery of the programme overseen by Lean Life Science.
Antidote
DECEMBER 19, 2022
Though nephropathy and neuropathy are two medical terms that sound similar, they refer to conditions that are very different. Nephropathy is a term related to disease or damage of the kidneys , while neuropathy is a term related to damage of the nervous system.
Drug Patent Watch
DECEMBER 23, 2022
Annual Drug Patent Expirations for RYANODEX Ryanodex is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent expiration for Eagle Pharms drug RYANODEX appeared first on DrugPatentWatch - Make Better Decisions.
keypoint
DECEMBER 20, 2022
The Keystone Symposia "New Frontiers in Reconstructing Human Evolution History," will feature the newly minted 2022 Nobel Laureate Svante Pääbo as the Keynote Speaker, in May of 2023!
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
New Drug Approvals
DECEMBER 19, 2022
Olutasidenib FT-2102 FT2102 C 18 H 15 ClN 4 O 2 354.79 CAS1887014-12-1 Rezlidhia (Forma Therapeutics) SYN Caravella JA, et al. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. FDA 12/1/2022, To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, Rezlidhia Olutasidenib
Antidote
DECEMBER 21, 2022
Hunter syndrome and Hurler syndrome are similar conditions with similar names — and as such, they are often confused. Both Hunter syndrome and Hurler syndrome are a result of genetic mutations that cause a build-up of toxins within the cells, and both result in similar symptoms. However, these conditions have different causes that are important to note.
Drug Patent Watch
DECEMBER 22, 2022
Annual Drug Patent Expirations for EPIDUO Epiduo is a drug marketed by Galderma Labs Lp and Galderma Labs and is included in two NDAs. It is available from two suppliers.…. The post New patent expiration for Galderma Labs drug EPIDUO appeared first on DrugPatentWatch - Make Better Decisions.
Cytel
DECEMBER 19, 2022
Adaptive trial designs – that is, trials that include a prospectively planned modification based on an interim analysis – have been traditionally associated with greater efficiency and better prospects for patients without compromising statistical rigor, and new holistic approaches to creating these designs are making room for transformative, even revolutionary, changes to strategic drug development.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PPD
DECEMBER 19, 2022
PPD, Thermo Fisher Scientific ’s clinical research business, surveyed more than 150 decision-making leaders at pharmaceutical and biotech companies around the globe to collect key insights on the state of the evolving drug development industry. Drug developers shared the disruptive impact of the COVID-19 pandemic and ever-changing industry landscape, which resulted in increased challenges in clinical trial execution.
Drug Channels
DECEMBER 19, 2022
Value-Based Care Summit. Accelerating Healthcare’s Shift in the Move from Volume to Value. In-Person Event | January 26-27, 2023 | Boston, MA www.thinc360.com/value. Use promo code VBCDC to save $100. Register Today. View the Agenda Snapshot. As healthcare stakeholders continue to prioritize the move to value-based care and aim to provide equitable access to care for all, leaders must develop novel approaches to empower the patient and ensure effective risk-sharing strategies.
Drug Patent Watch
DECEMBER 22, 2022
Annual Drug Patent Expirations for QELBREE Qelbree is a drug marketed by Supernus Pharms and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Supernus Pharms drug QELBREE appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
DECEMBER 17, 2022
To anyone who needs a few more CLE hours before the end of the 2022, we wanted to let you know that sessions from Reed Smith’s recent Life Sciences CLE Week are now available on demand. Here are descriptions of the topics, and registration links. The Ebb and Flow of the Law – A Year of Drug, Medical Device, and Vaccine-Related Preemption Developments | Presented by Blogger Jim Beck | Preemption is the most powerful defense in prescription medical product liability litigation.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
DECEMBER 22, 2022
Annual Drug Patent Expirations for EPIDUO+FORTE Epiduo Forte is a drug marketed by Galderma Labs and is included in one NDA. It is available from three suppliers. There are nine…. The post New patent expiration for Galderma Labs drug EPIDUO FORTE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 22, 2022
Annual Drug Patent Expirations for AUVELITY Auvelity is a drug marketed by Axsome and is included in one NDA. There are ninety-three patents protecting this drug. This drug has one…. The post New patent for Axsome drug AUVELITY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 21, 2022
This chart shows the pharmaceutical companies with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 21, 2022
Annual Drug Patent Expirations for BIJUVA Bijuva is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are twenty-one patents…. The post New patent for Therapeuticsmd Inc drug BIJUVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 21, 2022
Annual Drug Patent Expirations for TAZVERIK Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this drug. This drug has…. The post New patent for Epizyme Inc drug TAZVERIK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 21, 2022
Annual Drug Patent Expirations for ANNOVERA Annovera is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Therapeuticsmd Inc drug ANNOVERA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 20, 2022
Annual Drug Patent Expirations for MYCAPSSA Mycapssa is a drug marketed by Amryt and is included in one NDA. It is available from one supplier. There are nine patents protecting…. The post New patent for AMRYT drug MYCAPSSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 20, 2022
Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. It is available from one supplier. There are twelve…. The post New patent for Exeltis Usa drug SLYND appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 20, 2022
Annual Drug Patent Expirations for RINVOQ Rinvoq is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Abbvie Inc drug RINVOQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 20, 2022
Annual Drug Patent Expirations for LYVISPAH Lyvispah is a drug marketed by Amneal and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for Amneal drug LYVISPAH appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 20, 2022
Annual Drug Patent Expirations for DROSPIRENONE Drospirenone is a drug marketed by Exeltis Usa Inc, Barr, Glenmark Pharms Ltd, Hetero Labs, Hlthcare, Jubilant Cadista, Mylan Labs Ltd, Watson Labs, Apotex,…. The post New patent for Exeltis Usa drug DROSPIRENONE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 19, 2022
This chart shows the pharmaceutical companies with the most patents in Sweden. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 19, 2022
[
Drug Patent Watch
DECEMBER 19, 2022
[
Drug Patent Watch
DECEMBER 18, 2022
This chart shows the pharmaceutical companies with the most liquid dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most liquid dosed drugs…. The post Which pharmaceutical companies have the most liquid dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content